Medtronic Posts 8.7% Revenue Rise and 25-Year Dividend Growth
Medtronic posted 8.74% year-over-year revenue growth to $9.017 billion in its latest quarter, led by 13.8% gains in cardiovascular and 14.8% growth in diabetes sales. The stock’s low beta of 0.729 and 25-year streak of dividend increases, currently at $0.71 per share, underpins its appeal as a defensive healthcare investment.
1. Quarterly Financial Performance
Medtronic generated $9.017 billion in revenue during the most recent quarter, marking an 8.74% increase year-over-year. Growth was driven by cardiovascular segment sales up 13.8% and diabetes care revenue rising 14.8%.
2. Defensive Profile and Beta
With a beta of just 0.729, Medtronic demonstrates lower volatility than the broader market. This defensive positioning appeals to investors seeking stability in healthcare amid uncertain market conditions.
3. Dividend Track Record
Medtronic has increased its quarterly dividend for over 25 consecutive years, currently paying $0.71 per share. Consistent dividend growth underscores the company’s cash flow strength and commitment to returning capital to shareholders.
4. Analyst Outlook and Valuation
Analysts maintain a consensus price target of $111.69, compared to a current share price near $90.90. This outlook implies potential upside based on steady revenue expansion and reliable dividend payouts.